Acne Vulgaris - Pipeline Review, H2 2017

  • ID: 4410073
  • Report
  • 201 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Cassiopea SpA
  • Dermira Inc
  • Galderma SA
  • Melinta Therapeutics Inc
  • Pfizer Inc
  • MORE
Acne Vulgaris - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 20, 9, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Cassiopea SpA
  • Dermira Inc
  • Galderma SA
  • Melinta Therapeutics Inc
  • Pfizer Inc
  • MORE
Introduction

Acne Vulgaris - Overview

Acne Vulgaris - Therapeutics Development

Acne Vulgaris - Therapeutics Assessment

Acne Vulgaris - Companies Involved in Therapeutics Development

Acne Vulgaris - Drug Profiles

Acne Vulgaris - Dormant Projects

Acne Vulgaris - Discontinued Products

Acne Vulgaris - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Acne Vulgaris, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Acne Vulgaris - Pipeline by 3SBio Inc, H2

Acne Vulgaris - Pipeline by Almirall SA, H2

Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2

Acne Vulgaris - Pipeline by BioPharmX Inc, H2

Acne Vulgaris - Pipeline by Blueberry Therapeutics Ltd, H2

Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H2

Acne Vulgaris - Pipeline by Brickell Biotech Inc, H2

Acne Vulgaris - Pipeline by Cassiopea SpA, H2

Acne Vulgaris - Pipeline by Celtaxsys Inc, H2

Acne Vulgaris - Pipeline by Common Pharma Inc, H2

Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2

Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, H2

Acne Vulgaris - Pipeline by Dermira Inc, H2

Acne Vulgaris - Pipeline by Eligo Bioscience SAS, H2

Acne Vulgaris - Pipeline by ELORAC Inc, H2

Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H2

Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H2

Acne Vulgaris - Pipeline by Galderma SA, H2

Acne Vulgaris - Pipeline by Helix BioMedix Inc, H2

Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2

Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H2

Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2

Acne Vulgaris - Pipeline by LEO Pharma A/S, H2

Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H2

Acne Vulgaris - Pipeline by Novabiotics Ltd, H2

Acne Vulgaris - Pipeline by Novan Inc, H2

Acne Vulgaris - Pipeline by Novartis AG, H2

Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H2

Acne Vulgaris - Pipeline by Pfizer Inc, H2

Acne Vulgaris - Pipeline by Phagelux Inc, H2

Acne Vulgaris - Pipeline by Phosphagenics Ltd, H2

Acne Vulgaris - Pipeline by Photocure ASA, H2

Acne Vulgaris - Pipeline by Promius Pharma LLC, H2

Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H2

Acne Vulgaris - Pipeline by Realm Therapeutics Plc, H2

Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2

Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H2

Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, H2

Acne Vulgaris - Pipeline by Taro Pharmaceutical Industries Ltd, H2

Acne Vulgaris - Pipeline by Thesan Pharmaceuticals Inc, H2

Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H2

Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H2

Acne Vulgaris - Pipeline by XBiotech Inc, H2

Acne Vulgaris - Dormant Projects, H2

Acne Vulgaris - Dormant Projects, H2 2017 (Contd..1), H2

Acne Vulgaris - Dormant Projects, H2 2017 (Contd..2), H2

Acne Vulgaris - Dormant Projects, H2 2017 (Contd..3), H2

Acne Vulgaris - Dormant Projects, H2 2017 (Contd..4), H2

Acne Vulgaris - Discontinued Products, H2

List of Figures

Number of Products under Development for Acne Vulgaris, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • Almirall SA
  • Biomar Microbial Technologies
  • BioPharmX Inc
  • Blueberry Therapeutics Ltd
  • Braintree Laboratories Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Celtaxsys Inc
  • Common Pharma Inc
  • Cutanea Life Sciences Inc
  • Deltanoid Pharmaceuticals Inc
  • Dermira Inc
  • Eligo Bioscience SAS
  • ELORAC Inc
  • Ensol Biosciences Inc
  • Foamix Pharmaceuticals Ltd
  • Galderma SA
  • Helix BioMedix Inc
  • Hovione FarmaCiencia SA
  • Innovation Pharmaceuticals Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Melinta Therapeutics Inc
  • Novabiotics Ltd
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phagelux Inc
  • Phosphagenics Ltd
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Realm Therapeutics Plc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries Ltd
  • Thesan Pharmaceuticals Inc
  • Valeant Pharmaceuticals International Inc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll